PT860430E - Derivados e2 de omega-cicloalquil-prostaglandina - Google Patents

Derivados e2 de omega-cicloalquil-prostaglandina

Info

Publication number
PT860430E
PT860430E PT98300769T PT98300769T PT860430E PT 860430 E PT860430 E PT 860430E PT 98300769 T PT98300769 T PT 98300769T PT 98300769 T PT98300769 T PT 98300769T PT 860430 E PT860430 E PT 860430E
Authority
PT
Portugal
Prior art keywords
alkoxy
alkyl
halogen atom
omega
derivatives
Prior art date
Application number
PT98300769T
Other languages
English (en)
Inventor
Shuichi Ohuchida
Kousuke Tani
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of PT860430E publication Critical patent/PT860430E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
PT98300769T 1997-02-04 1998-02-03 Derivados e2 de omega-cicloalquil-prostaglandina PT860430E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP3549997 1997-02-04
JP31916997 1997-11-06

Publications (1)

Publication Number Publication Date
PT860430E true PT860430E (pt) 2002-11-29

Family

ID=26374500

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98300769T PT860430E (pt) 1997-02-04 1998-02-03 Derivados e2 de omega-cicloalquil-prostaglandina

Country Status (13)

Country Link
US (3) US6110969A (pt)
EP (1) EP0860430B1 (pt)
KR (1) KR100573535B1 (pt)
AT (1) ATE219054T1 (pt)
AU (1) AU736271B2 (pt)
CA (1) CA2228828A1 (pt)
DE (1) DE69805874T2 (pt)
DK (1) DK0860430T3 (pt)
ES (1) ES2178808T3 (pt)
HU (1) HUP9800208A3 (pt)
NO (1) NO317155B1 (pt)
PT (1) PT860430E (pt)
TW (1) TW581756B (pt)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998027976A1 (en) 1996-12-20 1998-07-02 Pfizer Inc. Prevention and treatment of skeletal disorder with ep2 receptor subtype selective prostaglandin e2 agonists
US6235780B1 (en) * 1998-07-21 2001-05-22 Ono Pharmaceutical Co., Ltd. ω-cycloalkyl-prostaglandin E1 derivatives
PL350917A1 (en) 1999-03-05 2003-02-10 Procter & Gamble C16 unsaturated fp-selective prostaglandins analogs
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
CA2416709A1 (en) * 2000-07-31 2003-01-17 Ono Pharmaceutical Co., Ltd. Therapeutic agent for erectile dysfunction containing as the active ingredient prostaglandin derivatives
US6410591B1 (en) * 2001-05-08 2002-06-25 Allergan Sales, Inc. 3,7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
US20030027853A1 (en) 2001-06-14 2003-02-06 Allergan Sales, Inc. 3, 7or3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
US7872045B2 (en) 2001-06-14 2011-01-18 Allergan, Inc. Combination therapy for glaucoma treatment
JP2006021998A (ja) * 2002-07-18 2006-01-26 Ono Pharmaceut Co Ltd Ep2アゴニストを有効成分とする月経困難症治療剤
US7737182B2 (en) 2002-08-09 2010-06-15 Taisho Pharmaceutical Co., Ltd. Pharmaceuticals for xerosis
JP3678366B2 (ja) * 2002-08-09 2005-08-03 大正製薬株式会社 止痒剤
AU2003272963A1 (en) * 2002-10-10 2004-05-04 Ono Pharmaceutical Co., Ltd. Endogenous repair factor production promoters
JP4477504B2 (ja) * 2002-11-13 2010-06-09 大正製薬株式会社 鎮痒剤
WO2004073591A2 (en) * 2003-02-24 2004-09-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep2 (prostaglandin e2 ep2)
JPWO2004089411A1 (ja) * 2003-04-03 2006-07-06 小野薬品工業株式会社 脊柱管狭窄症治療剤
US20070270489A1 (en) * 2003-07-25 2007-11-22 Ono Pharmaceutical Co., Ltd. Remedy for Cartilage-Related Diseases
US7858650B2 (en) 2004-10-22 2010-12-28 Ono Pharmaceutical Co., Ltd. Medicinal composition for inhalation
MY158766A (en) * 2005-04-11 2016-11-15 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
MY145694A (en) * 2005-04-11 2012-03-30 Xenon Pharmaceuticals Inc Spiroheterocyclic compounds and their uses as therapeutic agents
TWI404529B (zh) 2005-06-03 2013-08-11 Ono Pharmaceutical Co 神經再生及/或保護劑
US7563924B2 (en) * 2005-11-21 2009-07-21 Schering Aktiengesellschaft 9-chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments
SI1976828T1 (sl) 2005-12-29 2017-07-31 Celtaxsys, Inc. Diaminski derivati kot inhibitorji levkotrien A4 hidrolaze
BRPI0719210A2 (pt) 2006-10-12 2015-05-05 Xenon Pharmaceuticals Inc Uso de compostos espiro-oxindol como agentes terapêuticos
RU2009117605A (ru) * 2006-10-12 2010-11-20 Ксенон Фармасьютикалз Инк. (Ca) ПРОИЗВОДНЫЕ СПИРО-(ФУРО[3,2-c]ПИРИДИН-3-3'-ИНДОЛ)-2'(1'H)-ОНА И РОДСТВЕННЫЕ ИМ СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ ОПОСРЕДОВАННЫХ НАТРИЕВЫМИ КАНАЛАМИ ЗАБОЛЕВАНИЙ, ТАКИХ КАК БОЛЬ
US8183286B2 (en) 2006-11-16 2012-05-22 Gemmus Pharma Inc. EP2 and EP4 agonists as agents for the treatment of influenza a viral infection
US7960378B2 (en) * 2008-03-18 2011-06-14 Allergan, Inc. Therapeutic compounds
EP2149552A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors
EP2149554A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Indolylamide als Modulatoren des EP2-Rezeptors
EP2149551A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors
SI2350090T1 (sl) 2008-10-17 2015-10-30 Xenon Pharmaceuticals Inc. Spojine spiro-oksindola in njihova uporaba kot terapevtska sredstva
CA2741024A1 (en) * 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8623918B2 (en) 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
WO2011047173A2 (en) * 2009-10-14 2011-04-21 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
KR20120099429A (ko) 2009-10-14 2012-09-10 제논 파마슈티칼스 인크. 스피로-옥스인돌 화합물의 합성 방법
PE20121699A1 (es) 2010-02-26 2012-12-22 Xenon Pharmaceuticals Inc Composiciones farmaceuticas del compuesto espiro-oxindol para administracion topica
EP2740724B1 (en) * 2011-08-05 2016-12-28 ONO Pharmaceutical Co., Ltd. Compound for treating cartilage disorders
WO2013028470A1 (en) * 2011-08-19 2013-02-28 Merck Sharp & Dohme Corp. Process and intermediates for preparing macrolactams
RU2474426C1 (ru) * 2011-12-26 2013-02-10 Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН Простамиды и их аналоги, обладающие нейрозащитным действием
ES2714314T3 (es) 2012-04-12 2019-05-28 Xenon Pharmaceuticals Inc Síntesis asimétrica para compuestos de espiro-oxindol útiles como agentes terapéuticos
ES2733998T3 (es) 2012-10-29 2019-12-03 Cardio Incorporated Agente terapéutico específico de enfermedad pulmonar
EP2968264A4 (en) 2013-03-14 2016-11-02 Celtaxsys Inc INHIBITORS OF LEUCOTRIENE A4 HYDROLASE
EP2818484A1 (en) 2013-06-28 2014-12-31 Universitat Autònoma de Barcelona Synergistic combination of an anti-IgE antibody and an EP2 receptor agonist
US9968716B2 (en) 2013-10-15 2018-05-15 Ono Pharmaceutical Co., Ltd. Drug-eluting stent graft
TW201636017A (zh) 2015-02-05 2016-10-16 梯瓦製藥國際有限責任公司 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法
WO2017218920A1 (en) 2016-06-16 2017-12-21 Teva Pharmaceuticals International Gmbh Asymmetric synthesis of funapide
US10385007B2 (en) 2016-12-09 2019-08-20 Celtaxsys, Inc. Monamine and monoamine derivatives as inhibitors of leukotriene A4 hydrolase
AU2017371348B2 (en) 2016-12-09 2022-02-03 Celltaxis, Llc Inhibitors of leukotriene A4 hydrolase
WO2018107167A1 (en) 2016-12-09 2018-06-14 Celtaxsys, Inc. Pendant amines and derivatives as inhibitors of leukotriene a4 hydrolase

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4061670A (en) * 1976-07-19 1977-12-06 American Cyanamid Company 15-Deoxy-16-hydroxy-16-vinyl and cyclopropyl substituted prostanoic acids and congeners
US4132738A (en) * 1978-02-23 1979-01-02 Miles Laboratories, Inc. Preparation of 15-deoxy-16-hydroxyprostaglandins
US4336404A (en) * 1979-05-14 1982-06-22 Miles Laboratories, Inc. 1-Acyloxy-15-deoxy-16-hydroxy-analogs of prostaglandin E1
US4363817A (en) * 1981-08-27 1982-12-14 Miles Laboratories, Inc. Enol acylate analogs of E1 and E2 prostaglandins
US5698598A (en) * 1995-08-04 1997-12-16 Allergan EP2 -receptor agonists as agents for lowering intraocular pressure

Also Published As

Publication number Publication date
US6576785B1 (en) 2003-06-10
DE69805874T2 (de) 2002-12-19
EP0860430A2 (en) 1998-08-26
AU5289298A (en) 1998-08-06
ATE219054T1 (de) 2002-06-15
NO980442D0 (no) 1998-02-02
EP0860430B1 (en) 2002-06-12
CA2228828A1 (en) 1998-08-04
EP0860430A3 (en) 1999-06-23
KR19980071021A (ko) 1998-10-26
NO317155B1 (no) 2004-08-30
ES2178808T3 (es) 2003-01-01
HUP9800208A2 (hu) 1998-09-28
NO980442L (no) 1998-08-05
US20030186939A1 (en) 2003-10-02
DK0860430T3 (da) 2002-09-09
US6110969A (en) 2000-08-29
DE69805874D1 (de) 2002-07-18
KR100573535B1 (ko) 2006-12-15
HU9800208D0 (en) 1998-03-30
AU736271B2 (en) 2001-07-26
HUP9800208A3 (en) 2000-04-28
TW581756B (en) 2004-04-01

Similar Documents

Publication Publication Date Title
PT860430E (pt) Derivados e2 de omega-cicloalquil-prostaglandina
DE69901658T2 (de) Omega-Zykloalkyl-Prostaglandin E1 Derivate
DE69821987D1 (de) Omega-cycloalkyl-prostaglandin e2 derivate
DK0791006T3 (da) Polyanioniske benzylglylcosider som inhibitorer af proliferation af glatte muskelceller
ATE205206T1 (de) Benzylidenthiazolidinderivate, ihre herstellung und ihre anwendung als lipidperoxid-inhibitoren
PT918776E (pt) Sintese total de acilfulvenos antitumorais
HUP9601176A2 (hu) Adhéziós receptor antagonista amidinszármazékok, az ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
AU2888892A (en) 3-ureido-benzodiazepinones useful as antagonists of cck or of gastrine
KR940002233A (ko) 신규 제초제
DE69931051D1 (de) Neue vinylbenzolderivate
BR0213465A (pt) Compostos de 4-imidazolin-2-ona
DE69623497D1 (de) 1-methylcarbapenem-derivate
ATE239741T1 (de) Derivate der phosphonsäure zur inhibierung von carboxypeptidase b
ES2089041T5 (es) Compuestos de piridinasulfonamida sustituida, composiciones herbicidas que los contienen, y procedimiento para su preparacion.
ATE147073T1 (de) Hydantoin-derivate
CO4770918A1 (es) Compuestos de dihalopropeno insecticidas/acaricidas y compuestos intermediarios para su preparacion
ES2104761T3 (es) Derivado de benzotiazol.
HUP0301561A2 (hu) Triazintrion-szulfoxidok alkalmazása kokcidiózis elleni készítmények elżállítására
EP0798304A4 (en) DRUGS AGAINST TRHOMBOCYTOPENIA
KR950703575A (ko) 신규의 옥사 또는 아자스테로이드 7위치 치환 화합물 [novel 7-sunstituted oxa-or azasteroid compound]
DE60104110D1 (de) Benzoxazine zur verwendung in der behandlung parkinsonscher krankheit
TW200637553A (en) Indlomorphinane derivatives having a carboxy group at 6' position